{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "KRW", "regularMarketChangePercent": -1.2149532, "regularMarketPrice": 10570.0, "sharesOutstanding": 10881700, "fiftyDayAverage": 10851.4, "fiftyDayAverageChange": -281.4004, "fiftyDayAverageChangePercent": -0.025932172, "twoHundredDayAverage": 13184.3, "twoHundredDayAverageChange": -2614.2998, "twoHundredDayAverageChangePercent": -0.19828886, "marketCap": 115019571200, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1560297600000, "priceHint": 2, "marketState": "PREPRE", "exchange": "KOE", "shortName": "Aptabio", "longName": "AptaBio Therapeutics Inc.", "exchangeTimezoneName": "Asia/Seoul", "exchangeTimezoneShortName": "KST", "gmtOffSetMilliseconds": 32400000, "market": "kr_market", "esgPopulated": false, "regularMarketChange": -130.0, "regularMarketTime": 1683873030, "regularMarketDayHigh": 10650.0, "regularMarketDayRange": "10500.0 - 10650.0", "regularMarketDayLow": 10500.0, "regularMarketVolume": 63141, "regularMarketPreviousClose": 10700.0, "bid": 10570.0, "ask": 10600.0, "fullExchangeName": "KOSDAQ", "financialCurrency": "KRW", "regularMarketOpen": 10640.0, "averageDailyVolume3Month": 341200, "averageDailyVolume10Day": 101143, "fiftyTwoWeekLowChange": 900.0, "fiftyTwoWeekLowChangePercent": 0.09307136, "fiftyTwoWeekRange": "9670.0 - 27600.0", "fiftyTwoWeekHighChange": -17030.0, "fiftyTwoWeekHighChangePercent": -0.617029, "fiftyTwoWeekLow": 9670.0, "fiftyTwoWeekHigh": 27600.0, "symbol": "293780.KQ"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Tower 504, 13", "address2": "Heungdeok 1-ro Giheung-gu", "city": "Yongin-si", "zip": "16954", "country": "South Korea", "phone": "82 70 7152 0097", "fax": "82 3 1211 6697", "website": "https://www.aptabio.com", "industry": "", "sector": "", "longBusinessSummary": "AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jin Lee Soo", "title": "Chief Exec. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hwan Moon Sung", "title": "Pres & CSO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}